Clinical trials
Completed Observational Myelodysplastic Syndromes trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
97 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2002 | 1 |
| 2003 | 1 |
| 2004 | 2 |
| 2006 | 3 |
| 2007 | 11 |
| 2008 | 5 |
| 2009 | 6 |
| 2010 | 7 |
| 2011 | 5 |
| 2012 | 5 |
| 2013 | 4 |
| 2014 | 5 |
| 2015 | 2 |
| 2016 | 4 |
| 2017 | 3 |
| 2018 | 6 |
| 2019 | 3 |
| 2020 | 3 |
| 2021 | 5 |
| 2022 | 5 |
| 2024 | 3 |
| 2025 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 97 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Celgene | 13 |
| Bristol-Myers Squibb | 6 |
| Fred Hutchinson Cancer Center | 4 |
| Gruppo Italiano Malattie EMatologiche dell'Adulto | 3 |
| M.D. Anderson Cancer Center | 3 |
| Memorial Sloan Kettering Cancer Center | 3 |
| Children's Oncology Group | 2 |
| City of Hope Medical Center | 2 |
| Dana-Farber Cancer Institute | 2 |
| Janssen Korea, Ltd., Korea | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Myelodysplastic Syndromes | 97 |
| Leukemia, Myeloid, Acute | 32 |
| Leukemia | 25 |
| Myeloproliferative Disorders | 17 |
| Multiple Myeloma | 16 |
| Lymphoma | 15 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 14 |
| Leukemia, Myelomonocytic, Chronic | 13 |
| Lymphoma, Non-Hodgkin | 12 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 11 |
Trials
Showing 1 to 25 of 97. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.